Atossa Genetics (ATOS) Stock: This Thing Is Highly Undervalued

Atossa Genetics Inc (NASDAQ: ATOS) is having an incredible start to the trading session this morning. While the company did release news today, the news wasn’t all that big. Nonetheless, it seems as though investors are starting to realize that this stock is drastically undervalued. Before we get into the details here, we’d like to give a big thanks to our friends at Trade Ideas for being the first to alert us to the gains. Currently (10:06), ATOS is trading at $0.59 per share after a gain of $0.07 per share or 13.19% thus far today.





ATOS Announces Coming Presentation

While this type of announcement doesn’t generally lead to the type of gains that we’re seeing from Atossa Genetics today, it is a good thing for investors to follow. Early this morning, it was announced that Kyle Guse, CFO at ATOS, will be a featured presenter at the MicroCap Conference that will be held on Thursday October 5, 2017. The conference will be held at the Essex House in New York City. This news also has the potential to open doors for the company to key investors through one on one meetings.




This Stock Is Tremendously Undervalued

While the news released early this morning isn’t likely what’s causing the gains, the stock is flying for a good reason. Investors seem to be realizing the potential behind the company and that the intrinsic value of the company is far larger than what they are given credit for. The big key for ATOS is Endoxifen, a treatment designed for women with mammographic breast density or MBD.

Recently, ATOS announced that it has an upcoming Phase 2 clinical trial. In fact, the company has already contracted with a leading European hospital in order to conduct the trial. This could prove to be a massive value addition for ATOS considering that studies done by others have shown that when reduction of MBD takes place, the risk of developing breast cancer is drastically reduced. As a result, if all goes well through the studies, this could prove to be the goose that lays the golden eggs for Atossa Genetics. In a statement, DR. Steven C. Quay, CEO and President at ATOS, had the following to offer…

Dr. Hall is widely regarded as a leading researcher in the field of breast cancer and prevention. He is heading the unique KARMA (Karolinska Mammography Project for Risk Prediction of Breast Cancer) Cohort, including over 70,000 women, which is regarded as the best characterized breast cancer cohort in the world and serves as a resource for studies and breast cancer risk assessment and prevention, and the Karisma Intervention Study, which is studying the change in MBD in women taking various doses of oral tamoxifen. We are honored to be working with Dr. Hall and his colleagues on our Phase 2 study of MBD as their unique experience and qualifications are simply unmatched anywhere in the world.”

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on ATOS. In particular, we’re interested following the ongoing work the company is doing surrounding the treatment and prevention of breast cancer. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!
* indicates required









One Response

  1. Matthew Sep 30, 2017

Add Comment